The diagnostic value of the presence of anti-neuronal antibodies in serum was examined in 21 patients suspected of paraneoplastic disorders of the nervous system (NS) (group 1) and was compared to three control groups; group 2: 25 patients with a neurological disease, without cancer and no signs of paraneoplastic disorder; group 3: 27 patients with neurological disease and cancer and no signs of a paraneoplastic disorder; group 4: 94 patients with cancer and without neurological disease. In group 1, anti-neuronal nuclear antibodies were detected in eight patients (38%), in titres from 1:1000 to 1:32 000. A small cell lung cancer was present in six patients, ovarian cancer in one patient and in one patient no tumour could be detected. The neurological symptoms preceded a diagnosis of cancer in five out of eight patients. Anti-neuronal antibodies were found in the serum of two out of 94 patients (2%) from control group 3 but not in serum from any of the other control groups. These data indicate a moderate sensitivity of 38%, but a high specificity of 98-6% (95% confidence interval 95-5-99-8%) for the presence of anti-neuronal nuclear antibodies if a paraneoplastic NS disorder is suspected. As negative controls, sections were also incubated with PBS alone. To differentiate anti-neuronal antibodies from non-neuronal specific anti-nuclear antibodies, sera were also tested against frozen sections of normal human and rat liver. Stained sections were reviewed by the investigator and technician without previous knowledge of the patient's clinical status. Sera were considered positive for anti-neuronal antibodies only when distinct fluorescence staining was present in a titre of 1:500 or higher. Antibody-positive sera were also incubated with frozen sections of normal human and rat cerebral cortex, cerebellum, spinal cord, optical and vagal nerve.
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Four different categories of patients were distinguished: Group 1: patients with or without a verified cancer, in whom a reasonable or strong suspicion of a paraneoplastic NS disorder was present. Three case reports from this group have been described in detail7; For anti-Hu antibodies, Anderson et al found a specificity of almost 100% in a series of 18 patients with paraneoplastic NS disorder together with various control groups up to a total of 303 patients with or without cancer or neurological abnormalities.5 They found false positive antibodies in two patients with a possible paraneoplastic neurological syndrome, but without the presence of a malignancy. 5 We found positive auto-antibodies in two control patients of group 3. Two of these had a small cell lung cancer of the lung and positive titres of anti-neuronal nuclear antibodies. Neither of them had signs which are usually compatible with a paraneoplastic disorder of the NS. When we restrict ourselves to patients with positive titres of anti-neuronal 
